Art. -Nr.: HY-12033

2-Methoxyestradiol

(Synonyms: 2-ME2; NSC-659853)

33 Cited Publications

Kundenbewertung

Based on 33 publication(s) in Google Scholar

2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.76%
CAS. Nr.: 362-07-2
Formel: C₁₉H₂₆O₃
Molecular Weight:302.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

2-Methoxyestradiol Chemical Structure

CAS. Nr.: 362-07-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (33)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Human Endogenous Metabolite

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.1 μM Compound: 2ME2	Antitumour activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
B16	IC₅₀	3.4 μM Compound: 2ME2	Antitumour activity against mouse B16 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against mouse B16 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
Cancer cell lines	GI₅₀	0.08 μM Compound: 1	Cytotoxicity against the cancer cell lines breast MDA-MB-435 Cytotoxicity against the cancer cell lines breast MDA-MB-435	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.21 μM Compound: 1	Cytotoxicity against the cancer cell lines ovarian OVCAR-3 Cytotoxicity against the cancer cell lines ovarian OVCAR-3	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.32 μM Compound: 1	Cytotoxicity against the cancer cell lines CNS SF-539 Cytotoxicity against the cancer cell lines CNS SF-539	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.36 μM Compound: 1	Cytotoxicity against the cancer cell lines melanoma UACC-62 Cytotoxicity against the cancer cell lines melanoma UACC-62	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.47 μM Compound: 1	Cytotoxicity against the cancer cell lines colon HCT116 Cytotoxicity against the cancer cell lines colon HCT116	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.7 μM Compound: 2	Concentration required to inhibit the growth of HOP-6 human lung cancer cells by 50% Concentration required to inhibit the growth of HOP-6 human lung cancer cells by 50%	[PMID: 16078843]
Cancer cell lines	GI₅₀	0.7 μM Compound: 1	Cytotoxicity against the cancer cell lines lung HOP-62 Cytotoxicity against the cancer cell lines lung HOP-62	[PMID: 12361402]
Cancer cell lines	GI₅₀	0.95 μM Compound: 1	Cytotoxicity against the cancer cell lines renal SN12C Cytotoxicity against the cancer cell lines renal SN12C	[PMID: 12361402]
Cancer cell lines	GI₅₀	1.3 μM Compound: 1	Growth inhibitory concentration against human cancer cell line Growth inhibitory concentration against human cancer cell line	[PMID: 15456256]
Cancer cell lines	GI₅₀	1.8 μM Compound: 1	Cytotoxicity against the cancer cell lines prostate DU-145 Cytotoxicity against the cancer cell lines prostate DU-145	[PMID: 12361402]
DU-145	GI₅₀	1.2 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human DU145 cells at 96 hrs by WST1 assay Antiproliferative activity against human DU145 cells at 96 hrs by WST1 assay	[PMID: 22247790]
DU-145	GI₅₀	1.22 μM Compound: 1	Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay	[PMID: 17696419]
DU-145	GI₅₀	1.22 μM Compound: 1	Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
DU-145	GI₅₀	1.22 μM Compound: 1	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 18260615]
DU-145	GI₅₀	1.8 μM Compound: 2	Concentration required to inhibit the growth of DU-145 human prostate cancer cells by 50% Concentration required to inhibit the growth of DU-145 human prostate cancer cells by 50%	[PMID: 16078843]
DU-145	GI₅₀	1.8 μM Compound: 1	Growth inhibitory concentration against human prostate DU-145 cancer cell line Growth inhibitory concentration against human prostate DU-145 cancer cell line	[PMID: 15456256]
DU-145	GI₅₀	1.8 μM Compound: 1	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18052315]
DU-145	GI₅₀	1.8 μM Compound: 1	Cytotoxicity against prostate DU-145 cancer cell lines. Cytotoxicity against prostate DU-145 cancer cell lines.	[PMID: 7783135]
DU-145	GI₅₀	1.8 μM Compound: 1	The In vitro cytotoxicity value corresponding to 50% growth inhibition against DU-145 (prostate) cell line. The In vitro cytotoxicity value corresponding to 50% growth inhibition against DU-145 (prostate) cell line.	[PMID: 9240348]
ECa-109 cell line	IC₅₀	4.1 μM Compound: 2ME2	Antitumour activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
HCT-116	GI₅₀	0.47 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
HCT-116	GI₅₀	0.47 μM Compound: 2	Concentration required to inhibit the growth of HCT116 human colon cancer cells by 50% Concentration required to inhibit the growth of HCT116 human colon cancer cells by 50%	[PMID: 16078843]
HCT-116	GI₅₀	0.47 μM Compound: 1	Growth inhibitory concentration against human colon cancer HCT116 cell line Growth inhibitory concentration against human colon cancer HCT116 cell line	[PMID: 15456256]
HCT-116	GI₅₀	0.47 μM Compound: 1	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18052315]
HCT-116	GI₅₀	0.47 μM Compound: 1	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 18260615]
HCT-116	GI₅₀	0.47 μM Compound: 1	Cytotoxicity against colon HCT116 cancer cell lines. Cytotoxicity against colon HCT116 cancer cell lines.	[PMID: 7783135]
HCT-116	GI₅₀	0.47 μM Compound: 1	The In vitro cytotoxicity value is the concentration of the compound corresponding to 50% growth inhibition againstHCT-116 (colon) cell line. The In vitro cytotoxicity value is the concentration of the compound corresponding to 50% growth inhibition againstHCT-116 (colon) cell line.	[PMID: 9240348]
HEK-293T	IC₅₀	4.6 μM Compound: 2-methoxyestradiol	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
HeLa	IC₅₀	586 nM Compound: 2ME2	Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay	[PMID: 20973488]
HeLa	IC₅₀	608 nM Compound: 2ME2	Antiproliferative activity against human HeLa cells by sulforhodamine B assay Antiproliferative activity against human HeLa cells by sulforhodamine B assay	[PMID: 20973488]
HeLa	IC₅₀	8.6 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
HepG2	IC₅₀	11.03 μM Compound: 2; 2-ME2	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28810190]
HepG2	IC₅₀	2.3 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
HL-60	IC₅₀	0.9 μM Compound: Table 3 R4C1	Cytotoxicity against vincristine-resistant human HL60 cells after 72 hrs MTS assay Cytotoxicity against vincristine-resistant human HL60 cells after 72 hrs MTS assay	[PMID: 20411988]
HL-60	IC₅₀	3.4 μM Compound: Table 3 R4C1	Cytotoxicity against human HL60 cells after 72 hrs MTS assay Cytotoxicity against human HL60 cells after 72 hrs MTS assay	[PMID: 20411988]
HOP-62	GI₅₀	0.7 μM Compound: 1	Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
HOP-62	GI₅₀	0.7 μM Compound: 1	Growth inhibitory concentration against human lung cancer HOP-62 cell line Growth inhibitory concentration against human lung cancer HOP-62 cell line	[PMID: 15456256]
HOP-62	GI₅₀	0.7 μM Compound: 1	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 18052315]
HOP-62	GI₅₀	0.7 μM Compound: 1	Antiproliferative activity against human HOP62 cells Antiproliferative activity against human HOP62 cells	[PMID: 18260615]
HOP-62	GI₅₀	0.7 μM Compound: 1	Cytotoxicity against lung HOP-62 cancer cell lines. Cytotoxicity against lung HOP-62 cancer cell lines.	[PMID: 7783135]
HOP-62	GI₅₀	0.7 μM Compound: 1	The In vitro cytotoxicity value is the concentration corresponding to 50% growth inhibition against HOP-62 (non small cell lung) cell line. The In vitro cytotoxicity value is the concentration corresponding to 50% growth inhibition against HOP-62 (non small cell lung) cell line.	[PMID: 9240348]
HUVEC	IC₅₀	0.68 μM Compound: 2ME2, Panzem	Antiangiogenic activity against HUVEC assessed as growth inhibition after 48 hrs by WST1 assay Antiangiogenic activity against HUVEC assessed as growth inhibition after 48 hrs by WST1 assay	[PMID: 19782564]
HUVEC	IC₅₀	0.68 μM Compound: 2ME2	Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation	[PMID: 19782568]
HUVEC	IC₅₀	0.84 μM Compound: 1, 2ME2	Antiproliferative activity against human HUVECs after 48 hrs Antiproliferative activity against human HUVECs after 48 hrs	[PMID: 17910916]
HUVEC	IC₅₀	0.84 μM Compound: 2ME2	Antiangiogenic activity against HUVECs by Brdu incorporation assay Antiangiogenic activity against HUVECs by Brdu incorporation assay	[PMID: 19762246]
HUVEC	IC₅₀	0.84 μM Compound: 1	Growth inhibitory concentration against MDA-MB-231 cancer cell line Growth inhibitory concentration against MDA-MB-231 cancer cell line	[PMID: 15456256]
HUVEC	IC₅₀	14.17 μM Compound: 2; 2-ME2	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 28810190]
HUVEC	IC₅₀	523 nM Compound: 1	Antiangiogenic activity against HUVEC cells assessed as inhibition of proliferation Antiangiogenic activity against HUVEC cells assessed as inhibition of proliferation	[PMID: 18260615]
Ishikawa	IC₅₀	8.96 μM Compound: 2; 2-ME2	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 28810190]
K562	IC₅₀	0.8 μM Compound: 1, 2-ME	Anticancer activity against human K562 cells assessed as cell growth inhibition after 5 days by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 25108078]
LNCaP	IC₅₀	0.5 μM Compound: 6	Antiproliferative activity against human LNCaP cell line Antiproliferative activity against human LNCaP cell line	[PMID: 16650989]
MCF7	GI₅₀	2.35 μM Compound: 2	Inhibition of the growth of human breast cancer MCF-7 cells done for 2 hr at 37 degree C with compound Inhibition of the growth of human breast cancer MCF-7 cells done for 2 hr at 37 degree C with compound	[PMID: 16078843]
MCF7	GI₅₀	2.35 μM Compound: 1	Antiproliferative activity against estrogen receptor positive human MCF7 cells Antiproliferative activity against estrogen receptor positive human MCF7 cells	[PMID: 18260615]
MCF7	GI₅₀	2.35 μM Compound: 40	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 25992880]
MCF7	IC₅₀	>70 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
MCF7	IC₅₀	0.842 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet biomass reduction assay Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet biomass reduction assay	[PMID: 20334421]
MCF7	IC₅₀	2.39 μM Compound: 1 (2-MeOE2)	Anti-proliferative activity against MCF-7 human breast cancer cells was determined by using MCF-7 plate assay Anti-proliferative activity against MCF-7 human breast cancer cells was determined by using MCF-7 plate assay	[PMID: 15149660]
MCF7	IC₅₀	6.01 μM Compound: 2; 2-ME2	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28810190]
MDA-MB-231	GI₅₀	0.94 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST1 assay Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST1 assay	[PMID: 17696419]
MDA-MB-231	GI₅₀	0.94 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST-1 assay Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
MDA-MB-231	GI₅₀	0.94 μM Compound: 1	Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells	[PMID: 18260615]
MDA-MB-231	IC₅₀	0.25 μM Compound: 2-methoxyestradiol	Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 1 uM Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 1 uM	[PMID: 9357519]
MDA-MB-231	IC₅₀	0.79 μM Compound: 2ME2, Panzem	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by WST1 assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by WST1 assay	[PMID: 19782564]
MDA-MB-231	IC₅₀	0.79 μM Compound: 2ME2	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 19782568]
MDA-MB-231	IC₅₀	1 μM Compound: 1, 2ME2	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs Antiproliferative activity against human MDA-MB-231 cells after 48 hrs	[PMID: 17910916]
MDA-MB-231	IC₅₀	1 μM Compound: 1	Growth inhibitory concentration against HUVEC cancer cell line Growth inhibitory concentration against HUVEC cancer cell line	[PMID: 15456256]
MDA-MB-231	IC₅₀	5 μM Compound: 2-methoxyestradiol	Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 10 uM Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 10 uM	[PMID: 9357519]
MDA-MB-435	GI₅₀	0.08 μM Compound: 2	Concentration required to inhibit the growth of MDA-MB-435 human breast cancer cells by 50% Concentration required to inhibit the growth of MDA-MB-435 human breast cancer cells by 50%	[PMID: 16078843]
MDA-MB-435	GI₅₀	0.08 μM Compound: 1	Growth inhibitory concentration against human breast MDA-MB-435 cancer cell line Growth inhibitory concentration against human breast MDA-MB-435 cancer cell line	[PMID: 15456256]
MDA-MB-435	GI₅₀	0.08 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 18052315]
MDA-MB-435	GI₅₀	0.08 μM Compound: 1	Antiproliferative activity against human MDA-MB-435 cells Antiproliferative activity against human MDA-MB-435 cells	[PMID: 18260615]
MDA-MB-435	GI₅₀	0.08 μM Compound: 1	Cytotoxicity against breast MDA-MB-435 cancer cell lines. Cytotoxicity against breast MDA-MB-435 cancer cell lines.	[PMID: 7783135]
MDA-MB-435	GI₅₀	0.08 μM Compound: 1	In vitro cytotoxicity value corresponding to 50% growth inhibition against MDA-MB-435 (breast) cell line. In vitro cytotoxicity value corresponding to 50% growth inhibition against MDA-MB-435 (breast) cell line.	[PMID: 9240348]
MDA-MB-435	IC₅₀	1 μM Compound: 2ME2	Antiproliferative activity against human MDA-MB-435 cells by Brdu incorporation assay Antiproliferative activity against human MDA-MB-435 cells by Brdu incorporation assay	[PMID: 19762246]
MGC-803	IC₅₀	4 μM Compound: 2ME2	Antitumour activity against human MGC803 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against human MGC803 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	Antiproliferative activity against human OVCAR-3 cells after 96 hrs by WST-1 assay Antiproliferative activity against human OVCAR-3 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
OVCAR-3	GI₅₀	0.21 μM Compound: 2	Concentration required to inhibit the growth of OVCAR-3 human ovarian cancer cells by 50% Concentration required to inhibit the growth of OVCAR-3 human ovarian cancer cells by 50%	[PMID: 16078843]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	Growth inhibitory concentration against human ovarian OVCAR-3 cancer cell line Growth inhibitory concentration against human ovarian OVCAR-3 cancer cell line	[PMID: 15456256]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 18052315]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	Antiproliferative activity against human OVCAR-3 cells Antiproliferative activity against human OVCAR-3 cells	[PMID: 18260615]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	Cytotoxicity against ovarian OVCAR-3 cancer cell lines. Cytotoxicity against ovarian OVCAR-3 cancer cell lines.	[PMID: 7783135]
OVCAR-3	GI₅₀	0.21 μM Compound: 1	In vitro cytotoxicity value corresponding to 50% growth inhibition against OVCAR-3 (ovarian) cell line. In vitro cytotoxicity value corresponding to 50% growth inhibition against OVCAR-3 (ovarian) cell line.	[PMID: 9240348]
OVCAR-3	IC₅₀	1.2 μM Compound: 1, 2-ME	Anticancer activity against human OVCAR3 cells assessed as cell growth inhibition after 5 days by MTT assay Anticancer activity against human OVCAR3 cells assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 25108078]
Panel (Carcinoma cell lines)	GI₅₀	1.3 μM Compound: 1	Mean graph midpoint for all human cancer cell line cytotoxicity. Mean graph midpoint for all human cancer cell line cytotoxicity.	[PMID: 7783135]
Panel (Carcinoma cell lines)	GI₅₀	1.3 μM Compound: 1	Mean graph midpoint for growth inhibition of all human cancer cell lines Mean graph midpoint for growth inhibition of all human cancer cell lines	[PMID: 9240348]
PC-3	IC₅₀	12.31 μM Compound: 2; 2-ME2	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28810190]
PC-3	IC₅₀	2.65 μM Compound: 2ME2	Antiproliferative activity against human PC3 cells by Brdu incorporation assay Antiproliferative activity against human PC3 cells by Brdu incorporation assay	[PMID: 19762246]
PC-3	IC₅₀	82 μg/mL Compound: 2-ME2	Cytotoxicity against human PC3 cells after 72 hrs by CellTiter one aqueous solution assay Cytotoxicity against human PC3 cells after 72 hrs by CellTiter one aqueous solution assay	[PMID: 31195168]
SF-539	GI₅₀	0.32 μM Compound: 1	Antiproliferative activity against human SF539 cells after 96 hrs by WST-1 assay Antiproliferative activity against human SF539 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
SF-539	GI₅₀	0.32 μM Compound: 2	Concentration required to inhibit the growth of SF-539 human CNS cancer cells by 50% Concentration required to inhibit the growth of SF-539 human CNS cancer cells by 50%	[PMID: 16078843]
SF-539	GI₅₀	0.32 μM Compound: 1	Growth inhibitory concentration against human CNS SF-539 cancer cell line Growth inhibitory concentration against human CNS SF-539 cancer cell line	[PMID: 15456256]
SF-539	GI₅₀	0.32 μM Compound: 1	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 18052315]
SF-539	GI₅₀	0.32 μM Compound: 1	Antiproliferative activity against human SF539 cells at Antiproliferative activity against human SF539 cells at	[PMID: 18260615]
SF-539	GI₅₀	0.32 μM Compound: 1	Cytotoxicity against CNS SF-539 cancer cell lines. Cytotoxicity against CNS SF-539 cancer cell lines.	[PMID: 7783135]
SF-539	GI₅₀	0.32 μM Compound: 1	The In vitro cytotoxicity corresponding to 50% growth inhibition against SF-59 (central nervous system) cell line. The In vitro cytotoxicity corresponding to 50% growth inhibition against SF-59 (central nervous system) cell line.	[PMID: 9240348]
SK-N-SH	IC₅₀	1.6 μM Compound: 2ME2	Antitumour activity against human SK-N-SH cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against human SK-N-SH cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
SK-OV-3	IC₅₀	16.5 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
SK-OV-3	IC₅₀	2268 nM Compound: 2ME2	Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay	[PMID: 20973488]
SK-OV-3	IC₅₀	867 nM Compound: 2ME2	Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 20973488]
SMMC-7721	IC₅₀	8.4 μM Compound: 2ME2	Antitumour activity against human SMMC7721 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antitumour activity against human SMMC7721 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 31102934]
SN12C	GI₅₀	0.95 μM Compound: 1	Antiproliferative activity against human SN12C cells after 96 hrs by WST-1 assay Antiproliferative activity against human SN12C cells after 96 hrs by WST-1 assay	[PMID: 20225862]
SN12C	GI₅₀	0.95 μM Compound: 2	Concentration required to inhibit the growth of SN12C human renal cancer cells by 50% Concentration required to inhibit the growth of SN12C human renal cancer cells by 50%	[PMID: 16078843]
SN12C	GI₅₀	0.95 μM Compound: 1	Growth inhibitory concentration against human renal SN12C cancer cell line Growth inhibitory concentration against human renal SN12C cancer cell line	[PMID: 15456256]
SN12C	GI₅₀	0.95 μM Compound: 1	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 18052315]
SN12C	GI₅₀	0.95 μM Compound: 1	Antiproliferative activity against human SN12-C cells Antiproliferative activity against human SN12-C cells	[PMID: 18260615]
SN12C	GI₅₀	0.95 μM Compound: 1	Cytotoxicity against renal SN12C cancer cell lines. Cytotoxicity against renal SN12C cancer cell lines.	[PMID: 7783135]
SN12C	GI₅₀	0.95 μM Compound: 1	In vitro cytotoxicity value corresponding to 50% growth inhibition against SN12C (renal) cell line. In vitro cytotoxicity value corresponding to 50% growth inhibition against SN12C (renal) cell line.	[PMID: 9240348]
T47D	IC₅₀	25.2 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
U-87MG ATCC	IC₅₀	8.54 μM Compound: 2ME2	Antiproliferative activity against human U87MG cells by Brdu incorporation assay Antiproliferative activity against human U87MG cells by Brdu incorporation assay	[PMID: 19762246]
U-937	IC₅₀	2.91 μM Compound: 2-methoxyestradiol	Antiproliferative activity against human U937 cells by sulforhodamine B assay Antiproliferative activity against human U937 cells by sulforhodamine B assay	[PMID: 20334421]
UACC-62	GI₅₀	0.36 μM Compound: 1	Antiproliferative activity against human UACC62 cells after 96 hrs by WST-1 assay Antiproliferative activity against human UACC62 cells after 96 hrs by WST-1 assay	[PMID: 20225862]
UACC-62	GI₅₀	0.36 μM Compound: 2	Concentration required to inhibit the growth of UACC-62 human melanoma cells by 50% Concentration required to inhibit the growth of UACC-62 human melanoma cells by 50%	[PMID: 16078843]
UACC-62	GI₅₀	0.36 μM Compound: 1	Growth inhibitory concentration against human melanoma UACC-62 cancer cell line Growth inhibitory concentration against human melanoma UACC-62 cancer cell line	[PMID: 15456256]
UACC-62	GI₅₀	0.36 μM Compound: 1	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 18052315]
UACC-62	GI₅₀	0.36 μM Compound: 1	Antiproliferative activity against human UACC62 cells Antiproliferative activity against human UACC62 cells	[PMID: 18260615]
UACC-62	GI₅₀	0.36 μM Compound: 1	Cytotoxicity against melanoma UACC-62 cancer cell lines. Cytotoxicity against melanoma UACC-62 cancer cell lines.	[PMID: 7783135]
UACC-62	GI₅₀	0.36 μM Compound: 1	In vitro cytotoxicity value corresponding to 50% growth inhibition against UACC-62(melanoma) cell line. In vitro cytotoxicity value corresponding to 50% growth inhibition against UACC-62(melanoma) cell line.	[PMID: 9240348]

In Vitro

2-Methoxyestradiol (2-ME) (5-100 μM) inhibits assembly of purified tubulin in a concentration-dependent manner, with maximal inhibition (60%) at 200 μM 2-Methoxyestradiol (2ME2). In living interphase MCF7 cells at the IC₅₀ for mitotic arrest (1.2 μM), 2-Methoxyestradiol significantly suppresses the mean microtubule growth rate, duration and length, and the overall dynamicity, consistent with its effects in vitro, and without any observable depolymerization of microtubules. 2-Methoxyestradiol induces G₂-M arrest and apoptosis in many actively dividing cell types while sparing quiescent cells. 2-Methoxyestradiol binds to tubulin at or near the colchicine site, it inhibits microtubule assembly, and high concentrations have been shown to depolymerize microtubules in cells^[1].
2-Methoxyestradiol (2-ME) decreases the HIF-1α and HIF-2α nuclear staining in cells cultured under hypoxia. 2-Methoxyestradiol is an anti-angiogenic, anti-proliferative and pro-apoptotic agent that suppresses HIF-1α protein levels and its transcriptional activity. A significant decrease in the growth rate is found in the 10 μM 2-Methoxyestradiol-treated A549 cells in comparison with the DMSO-treated cells (66.2±7.2 and 101.2±2.3%, respectively; p=0.04) at 96 h. A significant increase in apoptosis is observed in cells treated with 10 μM 2-Methoxyestradiol in a normoxic condition in comparison with cells under lower O₂ concentration (5.8±0.2%; p=0.003)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To investigate the effect of 2-Methoxyestradiol (2-ME2) on uveitis development, C57BL/6 mice are randomly assigned into two groups and immunized with IRBP peptide. 2ME2 group starts 2-Methoxyestradiol (15 mg/kg) intraperitoneally from day 0 to day 13 while control group is given with vehicle. The disease score of 2-Methoxyestradiol (2ME2) group is 0.30±0.30, significantly lower than that of control group 2.09±0.28 (p<0.05), each group containing 5 mice^[3].
Treatment with 2-Methoxyestradiol (60-600 mg/kg/d) results in a dose-dependent inhibition of tumor growth. The percentage of cells with strong pimonidazole-positive staining (+++) is significantly decreased in the 2-Methoxyestradiol-treated group (36.0% for 60 mg/kg/d and 0% for 200 and 600 mg/kg/d) compare with the vehicle-treated group (86.5%). This may be attributed to the dramatic inhibition of tumor growth in a dose-dependent manner following 2-Methoxyestradiol treatment^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 362-07-2
Appearance Solid
Molecular Weight 302.41
Formel C₁₉H₂₆O₃
Color White to off-white
SMILES

OC1=CC2=C([C@]3(CC[C@@]4([C@H](CC[C@]4([C@@]3(CC2)[H])[H])O)C)[H])C=C1OC
Synonyms

2-ME2; NSC-659853
Structure Classification
- Phenols
- Monophenols
- Steroids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (33)

All WB

Sort by:

Journal Impact Factor

Cell Res

Asymmetric division in a two-cell-like state rejuvenates embryonic stem cells. [Abstract]

2026 Mar;36(3):219-232. PMID: 41634384
J Nanobiotechnology

Mesenchymal stem cells, as glioma exosomal immunosuppressive signal multipliers, enhance MDSCs immunosuppressive activity through the miR-21/SP1/DNMT1 positive feedback loop. [Abstract]

2023 Jul 22;21(1):233. PMID: 37481646
Theranostics

Energy competition remodels the metabolic glucose landscape of psoriatic epidermal cells. [Abstract]

2024 May 27;14(8):3339-3357. PMID: 38855186
J Exp Clin Cancer Res

Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. [Abstract]

2018 Jun 28;37(1):128. PMID: 29954442
Carbohydr Polym

Bioactive glycyrrhizic acid-astragalus polysaccharide hydrogel facilitates gastric ulcer healing via ROS scavenging and anti-apoptotic effects. [Abstract]

2025 Aug 15:362:123685. PMID: 40409809
Cell Death Dis

ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma. [Abstract]

2025 Jun 20;16(1):462. PMID: 40541964
Cancer Lett

Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. [Abstract]

2016 Nov 1;382(1):44-52. PMID: 27569654

2-Methoxyestradiol purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2016 Nov 1;382(1):44-52. [Abstract]

Downregulation of VEGF and HIF-1α by FP08S2 is dependent on Erk inactivation. VEGF and HIF-1α expression at protein level is detected after 2-ME treatment by Western blotting. 18S rRNA is used as internal control in qPCR while GAPDH is used as loading control in Western blotting.
Mol Ther

Exosomal miR-1246 from glioma patient body fluids drives the differentiation and activation of myeloid-derived suppressor cells. [Abstract]

2021 Dec 1;29(12):3449-3464. PMID: 34217892
Acta Biomater

Redox-responsive dendritic copolymer-drug conjugates enhance therapeutic mitophagy through coordinated microtubule destabilization for synergistic triple-negative breast cancer therapy. [Abstract]

2025 Aug:202:248-261. PMID: 40555336
J Transl Med

Fasting mimicking diet inhibits tumor-associated macrophage survival and pro-tumor function in hypoxia: implications for combination therapy with anti-angiogenic agent. [Abstract]

2023 Oct 26;21(1):754. PMID: 37884960
Free Radic Biol Med

Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from ferroptosis. [Abstract]

2021 Jun:169:271-282. PMID: 33895289
Stem Cell Res Ther

A dual role of HIF1α in regulating osteogenesis-angiogenesis coupling. [Abstract]

2022 Feb 5;13(1):59. PMID: 35123567
Front Immunol

Rapamycin Modulates the Proinflammatory Memory-Like Response of Microglia Induced by BAFF. [Abstract]

2021 May 12:12:639049. PMID: 34054807
Ann Hepatol

Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1α signaling pathway. [Abstract]

2023 Nov-Dec;28(6):101135. PMID: 37451514
Eur J Pharmacol

Inhibition of JAK1/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model. [Abstract]

2022 Oct 15:933:175276. PMID: 36130639
Cancer Biol Ther

HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia. [Abstract]

2016 Jun 2;17(6):625-34. PMID: 27082496

2-Methoxyestradiol purchased from MedChemExpress. Usage Cited in: Cancer Biol Ther. 2016 Jun 2;17(6):625-34. [Abstract]

HL-60 and Kasumi-1 cells are treated with different concentration of 2ME2 (0.1, 0.5, 2.5, or 5μM) for 24 hours or diluent control, and intracelluar protein levels are examined by Western blot.
Int J Mol Sci

A High-Calorie Diet Aggravates Lipopolysaccharide-Induced Pulmonary Inflammation in Juvenile Rats via Hypothalamic-Pituitary-Adrenal Axis-Related Pathways. [Abstract]

2025 Jul 8;26(14):6554. PMID: 40724811
Front Cell Dev Biol

Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-κB-VCAM-1 Signaling Pathway. [Abstract]

2021 Feb 23;9:607142. PMID: 33708767
Chem Biol Interact

Adverse effects of 2-Methoxyestradiol on mouse oocytes during reproductive aging. [Abstract]

2023 Jan 5:369:110277. PMID: 36414027
Pestic Biochem Physiol

2-Methoxyestradiol ameliorates paraquat-induced pulmonary fibrosis by inhibiting the TGF-β1/Smad2/3 signaling pathway. [Abstract]

2023 Dec:197:105647. PMID: 38072522
Rheumatology (Oxford)

Autophagy mediates 2-methoxyestradiol-inhibited scleroderma collagen synthesis and endothelial-to-mesenchymal transition induced by hypoxia. [Abstract]

2019 Nov 1;58(11):1966-1975. PMID: 31049569
Aquaculture

2020, 735393.
Front Cell Neurosci

IRAK-M Deficiency Exacerbates Ischemic Neurovascular Injuries in Experimental Stroke Mice. [Abstract]

2018 Dec 21:12:504. PMID: 30622459
Am J Physiol Lung Cell Mol Physiol

Intrauterine inflammation-induced neonatal lung injury via succinic acid-mediated alveolar epithelial E-cadherin downregulation. [Abstract]

2025 Aug 1;329(2):L282-L295. PMID: 40643013
Peptides

Cholecystokinin regulates atrial natriuretic peptide secretion through activation of NOX4-Sirt1-LEF1 signaling in beating rat hypoxic atria. [Abstract]

2024 Nov:181:171299. PMID: 39326462
J Immunol Res

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1 α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells. [Abstract]

2022 Apr 28;2022:6324326. PMID: 35528614
Biomed Res Int

2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation. [Abstract]

2016;2016:7948345. PMID: 27243036
Thorac Cancer

Mitochondrial NDUFA4L2 protein promotes the vitality of lung cancer cells by repressing oxidative stress. [Abstract]

2019 Apr;10(4):676-685. PMID: 30710412
Exp Ther Med

Hypoxia-inducible factor 1α participates in hypoxia-induced epithelial-mesenchymal transition via response gene to complement 32. [Abstract]

2017 Aug;14(2):1825-1831. PMID: 28810656

2-Methoxyestradiol purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2017 Aug;14(2):1825-1831. [Abstract]

HIF 1α regulates the protein levels of RGC 32 and epithelial mesenchymal transition associated genes induced by hypoxia. Proteins are extracted from cells after different treatments. Protein levels of HIF 1α, RGC 32, E cadherin, cytokeratins, N cadherin and vimentin are detected by western blotting. a, no treatment cells under normoxia; b, cells under hypoxia; c, cells are pretreated with HIF 1α inhibitor for 30 min, and then incubated under hypoxia; d, cells are transfected with negative contro
SSRN

2025 Mar 17.
Research Square Print

2022 Aug.
Research Square Print

2022 May.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (826.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3068 mL

16.5338 mL

33.0677 mL

5 mM

0.6614 mL

3.3068 mL

6.6135 mL

10 mM

0.3307 mL

1.6534 mL

3.3068 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

Microtubule protein (2.75 mg/mL) is assembled to steady-state [in 100 mM PIPES containing 1 mM EGTA and 1 mM MgSO₄ (PEM100) and 1 mM GTP, 35°C for 45 minutes] containing 2-Methoxyestradiol (final drug concentrations of 1-500 μM). Final DMSO and ethanol concentrations are adjusted to 1% and 5%, respectively. Concentrations of 2-Methoxyestradiol ≤ 5 μM have no effect on microtubule polymer mass, and thus 20 to 500 μM 2-Methoxyestradiol is used for most of the experiments. Incubation with 2-Methoxyestradiol is carried out for 30 minutes, at which time microtubule depolymerization is maximal, and microtubules are centrifuged at 35°C for 30 minutes and the supernatant is removed from the pellets. Microtubule pellets are solubilized overnight in 0.2 M NaOH and the protein concentrations of supernatants and pellets are determined^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

MCF7 breast carcinoma cells stably transfected with green fluorescent protein (GFP)-α-tubulin are cultured in DMEM supplemented with nonessential amino acids, 0.1% penicillin/streptomycin, 10% fetal bovine serum, and 0.4 mg/mL G418 at 37°C in 5% CO₂. Transfection of MCF7 cells with GFP-α-tubulin is carried out. To evaluate mitotic indices, cells are plated at a concentration of 6×10⁴/2 mL into six-well plates. After 48 hours, cells are incubated in the absence or presence of 2-Methoxyestradiol at concentrations ranging from 100 nM to 30 μM for 20 hours. To collect both floating and attached cells, medium is collected; attached cells are rinsed with Versene (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH₂PO₄, 8.1 mM Na₂HPO₄, and 0.5 mM EDTA), detached by trypsinization, and added back to the medium. Cells are collected by centrifugation and fixed with 10% formalin for 30 minutes, permeabilized in ice-cold methanol for 10 minutes, and stained with 4′,6-diamidino-2-phenylindole to visualize nuclei. Results are the mean and SE of seven experiments in each of which 500 cells are counted for each concentration. The mitotic IC₅₀ is the drug concentration that induced one half of the maximal mitotic accumulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
6~8-week-old C57BL/6 mice are used. C57BL/6 mice are immunized subcutaneously 0.1 mL at tail and 0.05 mL at both thigh sites with IRBP antigen complex. 500 ng Pertussis toxin is injected concurrently. This day is settled as day 0. Then mice are divided into 4 groups, each group containing 5 mice. 15 mg/kg 2-Methoxyestradiol or vehicle is abdominal injected during 0-13 days, 0-6 days, and 7-13 days. At day 14 eyes or lymphoglandula is collected after euthanasia.
Rats^[4]
Fischer 344 rats (average body weight=150 g, n=6 per group) are treated with an i.p. injection of the vehicle (60, 200, or 600 mg/kg/d of 2-Methoxyestradiol/Panzem) for nine consecutive days beginning on the 8th day after the initial tumor cell injection. The experiment is repeated a second time using three rats per group.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kamath K, et al. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther. 2006 Sep;5(9):2225-33. [Content Brief]

[2]. Aquino-Gálvez A, et al. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep. 2016 Jan;35(1):577-83. [Content Brief]

[3]. Xu L, et al. 2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation. Biomed Res Int. 2016;2016:7948345. [Content Brief]

[4]. Kang SH, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006, 66(24),11991-11997. [Content Brief]

[5]. LaVallee TM, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptorsalpha and beta. Cancer Res. 2002 Jul 1;62(13):3691-7. [Content Brief]

[6]. Chen Y, et al. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15(1):171-182. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3068 mL	16.5338 mL	33.0677 mL	82.6692 mL
	5 mM	0.6614 mL	3.3068 mL	6.6135 mL	16.5338 mL
	10 mM	0.3307 mL	1.6534 mL	3.3068 mL	8.2669 mL
	15 mM	0.2205 mL	1.1023 mL	2.2045 mL	5.5113 mL
	20 mM	0.1653 mL	0.8267 mL	1.6534 mL	4.1335 mL
	25 mM	0.1323 mL	0.6614 mL	1.3227 mL	3.3068 mL
	30 mM	0.1102 mL	0.5511 mL	1.1023 mL	2.7556 mL
	40 mM	0.0827 mL	0.4133 mL	0.8267 mL	2.0667 mL
	50 mM	0.0661 mL	0.3307 mL	0.6614 mL	1.6534 mL
	60 mM	0.0551 mL	0.2756 mL	0.5511 mL	1.3778 mL
	80 mM	0.0413 mL	0.2067 mL	0.4133 mL	1.0334 mL
	100 mM	0.0331 mL	0.1653 mL	0.3307 mL	0.8267 mL

Keywords

2-Methoxyestradiol

33 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

2-Methoxyestradiol

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Phenols Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Animal-Sourced Natural Product Library

Cell Death Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Lipid Metabolite Compound Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) 2-Methoxyestradiol

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (33)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

2-Methoxyestradiol Related Classifications

HY-12033 Related Classifications